RECENT BUY : (NYSE: GILD)

We Recently Purchased The Following:

Gilead Science, Inc (GILD)

Purchased 8 shares of GILD on 9/9/2016 at $78.53
Total Spent: $628.24; added $15.04 in forward dividends.

Our recent purchase of Gilead Science, Inc (GILD) is just the 3rd stock purchase made in our family's dividend stocks portfolio since February. We also bought Apple Inc (AAPL) and Flower Foods Inc (FLO), on June 24, 2016 and September 9, 2016, respectively. We hope the market continues to decline (as it did on Friday) so that we can continue grabbing a few more value buys! Not sure about you, but whether it is a stock or a consumer good, I love it when I can grab a good deal!  

Here are a few reasons why we believe GILD is a good buy: 1) GILD is trading at a 31.5% discount from its 52-week high; 2) Although the dividend is only 2.41%, their payout ratio is a low 16.4% which should allow GILD to continue to raise dividends for years to come; 3) GILD is a very large company with a market cap at 103.0 Billion.

Company Description

From Google Finance:

“Gilead Sciences, Inc. is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company's principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory. Its HIV products include Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost and Vitekta. The Company's liver diseases products include Harvoni, Sovaldi, Viread and Hepsera. The Company's cardiovascular products include Letairis, Ranexa and Lexiscan/Rapiscan. Its oncology product is Zydelig. Its respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen. The Company's Nimbus Apollo program is a Phase II ready clinical program for NDI-010976 and related metabolic and liver diseases.”

With our recent purchase of Gilead Science, Inc (GILD), the estimated forward dividends for our family's dividend stocks portfolio grew another $15.04, putting our yearly dividends at approximately $3,289/year (excluding our Edwards Jones account) and $3,674/year (including our Edward Jones account).  

Since did not previously own Gilead Science Inc, the recent buy of GILD added yet another dividend paying company to our family's dividend stocks portfolios (WF and EJ Accounts). The total stocks held in our family's dividend stock portfolio is now 56 different dividend paying stocks/ETFs and also 5 companies that either don't pay a dividend our has currently suspended their dividends.

Our family's dividend stocks portfolio may be found

by clicking on the link below:

DIVIDEND STOCKS PORTFOLIO

We also maintain an extensive list of stock analysis

that can be access through the link below:

COLLECTION OF STOCK ANALYSES

We also just started a list of Recent Buys by other bloggers

that can be access through the link below:

COLLECTION OF RECENT BUYS

HERE IS A QUICK FACT SHEET FOR THE STOCK I JUST PURCHASED:

Gilead Science, Inc (GILD)

P/E: 6.88

Payout Ratio: 16.4%
Dividend Yield:2.41%
1 consecutive years of dividend increases
Last Ex-dividend date: 6/14/2016

Next Ex-dividend date: approx. 9/14/2016
Have paid a dividend since: 2015 (1 year)
Pays a dividend 4 times a year
Market Cap: 103.0 Billion
52-week high: $113.31
52-week low: $76.67
Purchased Price: $78.53

What are your thoughts on of recent purchase?

What are you buying?